Harrow, Inc. (HROW): Gross Profit
$204.37M
Year ended 2025-12-31
$201.96M
Trailing 12 months to 2026-06-30
+47.9%
3-year compound annual growth
+42.8%
5-year compound annual growth
+46.4%
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $204.37M | +35.9% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $150.37M | +66.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $90.55M | +43.3% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $63.21M | +16.5% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $54.26M | +57.7% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $34.41M | 0.0% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $34.42M | +38.5% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $24.85M | +87.3% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $13.27M | +31.2% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $10.11M | +124.2% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $4.51M | +695.4% | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $567.0K | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | $10.0K | n/a | 2015-03-12, From 2013-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $204.37M | +35.9% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $127.10M | +150.3% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $142.61M | +8.0% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $197.11M | +8.1% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $275.75M | +584.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $196.73M | +102.8% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $170.21M | +2.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $120.87M | +48.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $322.17M | +20.2% |
Compare HROW, VREOF, SDGR, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗